Sep 29, 2026 8:30am EDT FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Sep 17, 2026 8:30am EDT FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
Sep 03, 2026 8:30am EDT FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Sep 01, 2026 8:30am EDT FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Aug 27, 2026 8:30am EDT FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Aug 20, 2026 8:30am EDT FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
Aug 18, 2026 8:30am EDT FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Aug 11, 2026 8:30am EDT FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets